High-risk anticholinergics

High-risk anticholinergics has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest story, Nov 6, 2026: “Bladder drugs presumed safer not linked to lower dementia risk”.

Intervention

1 paper studies it1 findingUpdated Nov 6, 2026

1 new paper in 30 daysSee all 1 papers on high-risk anticholinergics

At a glance

The findings reach people, from one lab or study. 1 lab.

“high-risk anticholinergics were associated with a lower hazard of dementia than β3 agonists (hazard ratio [HR], 0.90; 95% CI, 0.87-0.93)”

Drug Therapies and Incidence of Dementia Among Adults With Overactive BladderJAMA network open2026doi:10.1001/jamanetworkopen.2026.42026

1 lab

Humans1

What is high-risk anticholinergics linked with?

Studies link high-risk anticholinergics with 1 measure, most often incident dementia (1 study).

Incident dementia

downin humans1HR 0.9

1 study

High-risk anticholinergics are associated with incident dementia in humans (Overactive bladder; compared with β3 agonists; inverse probability of treatment weighting) (HR 0.90, 95% CI 0.87-0.93).
“high-risk anticholinergics were associated with a lower hazard of dementia than β3 agonists (hazard ratio [HR], 0.90; 95% CI, 0.87-0.93)”
HumansOveractive bladder; compared with β3 agonists; inverse probability of treatment weightingn = 830,393
Bladder drugs presumed safer not linked to lower dementia risk
JAMA network openNov 6, 2026

Latest

1 paper in 12 months

JAMA Network OpenNov 6

Bladder drugs presumed safer not linked to lower dementia risk

Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.

Cohort · 830,393 peopleIncident dementia

Paper